8/9/2019 Corporate Presentation of ranbaxy
1/26
Corporate PresentationJan 2010
8/9/2019 Corporate Presentation of ranbaxy
2/26
Safe Harbor
Except for the historical information contained herein, statements in this presentation and the
subsequent discussions, which include words or phrases such as will, aim, will likely result,
would, believe, may, expect, will continue, anticipate, estimate, intend, plan,
contemplate, seek to, future, objective, goal, likely, project, should, potential, will pursue
" "- .
These forward-looking statements involve a number of risks, uncertainties and other factors that could
cause actual results to differ materially from those suggested by the forward-looking statements. These
risks and uncertainties include, but are not limited to our ability to successfully implement our strategy,
our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological
c anges, nvestment an us ness ncome, cas ow pro ect ons, our exposure to mar et r s s as we
as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to
reflect events or circumstances after the date thereof.
8/9/2019 Corporate Presentation of ranbaxy
3/26
MissionTo become a Research-based International
Pharmaceutical Company
Achieve significant business
with a strong presence in developed markets
8/9/2019 Corporate Presentation of ranbaxy
4/26
Values
Achieving customer satisfaction is fundamental to our business
Provide products and services of the highest quality
Practice dignity and equity in relationship and provide opportunities for
our people to realise their full potential
Ensure profitable growth and enhance wealth of the shareholders
Foster mutually beneficial relations with all our business partners
Manage our operations with high concern for safety and environment
Be a responsible corporate citizen
8/9/2019 Corporate Presentation of ranbaxy
5/26
Ranbaxy Overview Indias largest pharmaceutical company
Ranbaxy & Daiichi Sankyo combined rank among the top 20 global
Worldwide Presence
Ground resence in 46 countries roducts sold in over 125 countries
Manufacturing locations in 7 countries
Global consolidated sales US $ 1519 Mn (2009)
Business
- International 77%
- Domestic 23%
>12000 employees globally represented by 50 nationalities
8/9/2019 Corporate Presentation of ranbaxy
6/26
8/9/2019 Corporate Presentation of ranbaxy
7/26
The Global Generics AdvantagesGrowth Potential
Patent Expiries ew ar ets
Healthcare Costs
Consolidation
Size & Scale
India Factor
Scientific Talent
Therapeutic Width
Operational Synergies
Cost Advantage Gx / Rx Competencies
Product Portfolio
Move to Specialty/ Niche
8/9/2019 Corporate Presentation of ranbaxy
8/26
Our Global Presence
North America Latin America
Europe Africa
Asia (incl. Middle East) Japan
8/9/2019 Corporate Presentation of ranbaxy
9/26
Business ModelGlobal Reach
Developed Markets
Product Portfolio
Generics, , ,
Emerging marketsIndia, Romania, CIS,
South Africa,
Branded & OTC
Brazil, Mexico Competitive Advantages
Aggressive Marketing Low cost of Innovation
ManufacturingResearch &Development
Global Management
Dosage Form API* - Vertical Integration In-house / Outsource
New Chemical Entities Generics / NDDS* Complex / Niche/ FTF*
The India advantage The India advantage
* NDDS - Novel Drug Delivery System, API Active Pharmaceutical Ingredients, FTF First to File
8/9/2019 Corporate Presentation of ranbaxy
10/26
Global Sales Split
AsiaCIS*
orAmerica
RoW
Europe
API
* CIS includes Russia & Ukraine belt
Global Sales (2009): US $ 1519 Mn
8/9/2019 Corporate Presentation of ranbaxy
11/26
Evolution of Market Mix
Emerging54%
Others
7%
Developed39%
FY 2005 FY 2009
Improving balance in market mix Growth well spread across geographies
os one o everage var ous mar e oppor un es
8/9/2019 Corporate Presentation of ranbaxy
12/26
Our Key Geographies
Pioneer entrant from IndiaStrong local presence
North America
Canada: New market, growing rapidly
Well established
EUROPE
Presence in 23 of 27 EU countriesNo. 1 Generic player in RomaniaKey markets - UK, France & Germany
Emerging Markets
Leadership in domestic market- IndiaEstd. Infrastructure in Romania, Brazil, Russia & South AfricaProfitable branded generics markets
8/9/2019 Corporate Presentation of ranbaxy
13/26
Developed Markets Presence
Largest generic market worldwide
Significant patent expiries through 2011USA
Germany, UK - mature markets
EU
France, Spain, Italy, Romania - emerging markets
Ranbaxy has presence in 23 of the 27 EU countries
Mature generic market
Ranbaxy is the fastest growing generics company in Canada
Emerging generic market, < 5% generic penetration
st
Japan
8/9/2019 Corporate Presentation of ranbaxy
14/26
Emerging Markets Presence
Leadership position in domestic market
Company growing faster than market
Ranked as the No 1 Generics Company
India
Strategic for servicing EU operationsRomania
Strong base in acute therapies
Fast expanding into chronic and OTC segments
Key market in the African continent
Ukraine
s rong o p ayer n e reg onSouth Africa
8/9/2019 Corporate Presentation of ranbaxy
15/26
India
Indias largest pharmaceutical company by sales and ranked No 2 by
market share
Company growing faster than market Company has one of the largest distribution networks that comprises
2500+ skilled field force
18 brands in Top 300 of Industry
8/9/2019 Corporate Presentation of ranbaxy
16/26
Research & Development
State-of-the-art R&D facilitiesbased in India
R&D III
R&D IV
8/9/2019 Corporate Presentation of ranbaxy
17/26
Research & Development
Dedicated Facilities for Innovative & Generics Research
> 1400 R&D Personnel ~ 300 Doctorates
Highest R&D spender across industry
8 - 10 NCE molecules in i eline
NDDS based products (4 platform technologies)
R&D collaborations
Alliance / Collaboration in
Alliance / Collaboration in
NDDR
Out-licensinOut-licensing
NDDR
In NDDSIn NDDR
8/9/2019 Corporate Presentation of ranbaxy
18/26
Our Global Manufacturing Strengths
cGMP compliant world-class API & Dosage Forms manufacturing facilities acrossthe globe
7 manufacturing locations worldwide API facilities - increasing vertical integration Creating capacities for specialty products New facilities added in cost advantageous geographies
USAUSA IrelandIreland NigeriaNigeriaRomaniaRomania
IndiaIndia MalaysiaMalaysiaSouth AfricaSouth Africa
8/9/2019 Corporate Presentation of ranbaxy
19/26
Inorganic Strategy
To capitalize on the opportunities in the ongoing consolidation for
Size and scale in developed & emerging markets
Expansion of geographical reach
Access to niche and complex products / therapeutic areas
Costs efficiencies in manufacturing and R&D
...providing a strategic and value accretive fit
8/9/2019 Corporate Presentation of ranbaxy
20/26
Acquisitions & Alliances Since 2006
> US $ 500 Mn spend on M&A
Tera ia Romania
Be-Tabs (South Africa)
Orchid (India)
Zenotech (India)
Ethimed (Belgium) Krebs (India)
Derma Brands (USA)
Cardinal Drugs (India)
-
8/9/2019 Corporate Presentation of ranbaxy
21/26
Ranbaxy Daiichi Sankyo Partnership
A path breaking confluence that redefines the global pharma paradigm
Combines complementary strengths rov es so ut ons to ey nee -gaps or eac organ sat on
Strategic combination creates an Innovator and Generic Pharmaceutical
Powerhouse
Combined entity is ranked among the Top 20 global pharmaceutical
Ranbaxy enters into a new orbit to chart a higher trajectory
Complementary strengths ranging from excellence in NDDR toextensive reach across global markets
Financially & strategically beneficial for all stakeholders
8/9/2019 Corporate Presentation of ranbaxy
22/26
To become a Global Pharma Innovator
Global Innovator
Achieve scientific and
Pharma
presenceworldwide
technologicalinnovations, create aninnovative business
Pharmaceuticals,develop novel
modeldrugs continuously
Complementary Business Combination
Global Pharma Innovator An Integrated, Research Based,
Company
8/9/2019 Corporate Presentation of ranbaxy
23/26
Corporate Social Responsibility
An essential component of Ranbaxys CSR is to care for thecommunity
Based on the theme Health For All set up Ranbaxy RuralDevelopment Trust in 1978; later re-christened as RanbaxyCommunity Health Care Society in 1994
Operates in the states of Punjab, Haryana, Himachal
Pradesh, Madhya Pradesh and Delhi/Gurgaon to providen egra e ea care o a ou a peop e s ay ng nvillages and urban slum areas
,promotive services covering areas of maternal child health,family planning, adolescent health, reproductive health andeducation
8/9/2019 Corporate Presentation of ranbaxy
24/26
Corporate Social Responsibility
AIDS awareness and counselling is a priority component ofthe CSR programme
Established meaningful and useful partnerships with theGovernment, Medical Colleges, NGOs, EducationalInstitutions, Confederation of Indian Industry and other likeminded agencies
Anti-Aids rov es nnovat ve an a or a e ant me c nes Over 5 lakh patients worldwide benefit from Ranbaxys
ARV drugs First in the world Pediatrics ARV
Malaria Research Molecule in Phase III Clinical Trials Intended for patients in developing/ countries
8/9/2019 Corporate Presentation of ranbaxy
25/26
Corporate Governance
An institutionalized framework of Corporate Governance and Code ofPractices to strengthen decision making and compliance with ethicalinte rit and reliabilit
Board Of Directors
Science Shareholder
Grievance/Transfer
Committees of the Board
Audit Compensation
Management
8/9/2019 Corporate Presentation of ranbaxy
26/26
Thank You